155 related articles for article (PubMed ID: 33040870)
1. Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors.
Coe CL; Horst SN; Izzy MJ
Neurol Clin; 2020 Nov; 38(4):937-951. PubMed ID: 33040870
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Song T; Rao Z; Tan Q; Qiu Y; Liu J; Huang Z; Wang X; Lin T
Medicine (Baltimore); 2016 Apr; 95(14):e3173. PubMed ID: 27057842
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review.
Verona P; Edwards J; Hubert K; Avorio F; Re VL; Di Stefano R; Carollo A; Johnson H; Provenzani A
Drug Saf; 2024 May; 47(5):419-438. PubMed ID: 38353884
[TBL] [Abstract][Full Text] [Related]
4. Posterior Reversible Encephalopathy Syndrome in Organ Transplantation.
Jeelani H; Sharma A; Halawa AM
Exp Clin Transplant; 2022 Jul; 20(7):642-648. PubMed ID: 35924741
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Wu Q; Marescaux C; Wolff V; Jeung MY; Kessler R; Lauer V; Chen Y
Eur Neurol; 2010; 64(3):169-77. PubMed ID: 20699617
[TBL] [Abstract][Full Text] [Related]
6. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
7. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol.
Souto-Rodríguez R; Molina-Pérez E; Castroagudín JF; Fernández Pérez A; Otero-Antón E; Tomé Martínez de Rituerto S; Martínez-Castro J; Varo-Pérez E
Transplant Proc; 2014 Nov; 46(9):3117-20. PubMed ID: 25420839
[TBL] [Abstract][Full Text] [Related]
8. Exploring the neuroregenerative potential of tacrolimus.
Saffari TM; Bedar M; Zuidam JM; Shin AY; Baan CC; Hesselink DA; Hundepool CA
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1047-1057. PubMed ID: 31575290
[No Abstract] [Full Text] [Related]
9. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Toledo Perdomo K; Navarro Cabello MD; Pérez Sáez MJ; Ramos Pérez MJ; Agüera Morales ML; Aljama García P
J Nephrol; 2012; 25(5):839-42. PubMed ID: 22252846
[TBL] [Abstract][Full Text] [Related]
10. Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities.
Zhang W; Egashira N; Masuda S
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261959
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
[TBL] [Abstract][Full Text] [Related]
12. Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients.
Erro R; Bacchin R; Magrinelli F; Tomei P; Geroin C; Squintani G; Lupo A; Zaza G; Tinazzi M
J Neurol; 2018 Jul; 265(7):1676-1683. PubMed ID: 29777361
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Bechstein WO
Transpl Int; 2000; 13(5):313-26. PubMed ID: 11052266
[TBL] [Abstract][Full Text] [Related]
14. Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Gaziev J; Marziali S; Paciaroni K; Isgrò A; Di Giuliano F; Rossi G; Marziali M; De Angelis G; Alfieri C; Ribersani M; Andreani M; Palmieri MG; Placidi F; Romigi A; Izzi F; Floris R; Mercuri NB
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1531-1540. PubMed ID: 28602890
[TBL] [Abstract][Full Text] [Related]
15. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?
Farouk SS; Rein JL
Adv Chronic Kidney Dis; 2020 Jan; 27(1):56-66. PubMed ID: 32147003
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
17. Late fulminant posterior reversible encephalopathy syndrome after liver transplant.
Heidenhain C; Puhl G; Neuhaus P
Exp Clin Transplant; 2009 Sep; 7(3):180-3. PubMed ID: 19715529
[TBL] [Abstract][Full Text] [Related]
18. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors.
Matsuda Y; Chen F; Miyata H; Date H
Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):171-3. PubMed ID: 24659549
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin-inhibitor induced pain syndrome after stem cell transplant.
Varma A; Loya J; Junaid Hussain M; Don Yun H; Gobbi EK; Reimer A; Nathan S; Ustun C; Muffly L
Leuk Lymphoma; 2020 Sep; 61(9):2230-2233. PubMed ID: 32431182
[No Abstract] [Full Text] [Related]
20. Basiliximab for posterior reversible encephalopathy syndrome after lung transplantation.
Yamagishi H; Chen-Yoshikawa TF; Date H
Eur J Cardiothorac Surg; 2017 Oct; 52(4):823-824. PubMed ID: 28498905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
